688 related articles for article (PubMed ID: 32259264)
1. Association of Long Noncoding RNA Biomarkers With Clinical Immune Subtype and Prediction of Immunotherapy Response in Patients With Cancer.
Yu Y; Zhang W; Li A; Chen Y; Ou Q; He Z; Zhang Y; Liu R; Yao H; Song E
JAMA Netw Open; 2020 Apr; 3(4):e202149. PubMed ID: 32259264
[TBL] [Abstract][Full Text] [Related]
2. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
3. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
4. Predictive role of ferroptosis-related long non-coding RNAs in bladder cancer and their association with immune microenvironment and immunotherapy response.
Liu J; Zhang Z; Liu X; Zhang W; Meng L; Wang J; Lv Z; Xia H; Zhang Y; Wang J
World J Surg Oncol; 2022 Feb; 20(1):47. PubMed ID: 35209909
[TBL] [Abstract][Full Text] [Related]
5. Identification of immune-related LncRNA for predicting prognosis and immunotherapeutic response in bladder cancer.
Wu Y; Zhang L; He S; Guan B; He A; Yang K; Gong Y; Li X; Zhou L
Aging (Albany NY); 2020 Nov; 12(22):23306-23325. PubMed ID: 33221763
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive
Xu T; Xu W; Zheng Y; Li X; Cai H; Xu Z; Zou Q; Yu B
Front Immunol; 2022; 13():931906. PubMed ID: 35958598
[TBL] [Abstract][Full Text] [Related]
7. Long noncoding RNAs to predict postoperative recurrence in bladder cancer and to develop a new molecular classification system.
Li Z; Jiang L; Zhang Z; Deng M; Wei W; Tang H; Guo S; Ye Y; Yao K; Liu Z; Zhou F
Cancer Med; 2022 Jan; 11(2):539-552. PubMed ID: 34816620
[TBL] [Abstract][Full Text] [Related]
8. POLQ identifies a better response subset to immunotherapy in muscle-invasive bladder cancer with high PD-L1.
Liu G; Jin K; Liu Z; Su X; Xu Z; Li B; Xu J; Chang Y; Wang Y; Zhu Y; Xu L; Xu J; Wang Z; Liu H; Zhang W
Cancer Med; 2024 Feb; 13(4):e6962. PubMed ID: 38457207
[TBL] [Abstract][Full Text] [Related]
9. Bioinformatics profiling utilized a nine immune-related long noncoding RNA signature as a prognostic target for pancreatic cancer.
Wei C; Liang Q; Li X; Li H; Liu Y; Huang X; Chen X; Guo Y; Li J
J Cell Biochem; 2019 Sep; 120(9):14916-14927. PubMed ID: 31016791
[TBL] [Abstract][Full Text] [Related]
10. Computational recognition of lncRNA signature of tumor-infiltrating B lymphocytes with potential implications in prognosis and immunotherapy of bladder cancer.
Zhou M; Zhang Z; Bao S; Hou P; Yan C; Su J; Sun J
Brief Bioinform; 2021 May; 22(3):. PubMed ID: 32382761
[TBL] [Abstract][Full Text] [Related]
11. Translation of the 27-gene immuno-oncology test (IO score) to predict outcomes in immune checkpoint inhibitor treated metastatic urothelial cancer patients.
Seitz RS; Hurwitz ME; Nielsen TJ; Bailey DB; Varga MG; Ring BZ; Metts CF; Schweitzer BL; McGregor K; Ross DT
J Transl Med; 2022 Aug; 20(1):370. PubMed ID: 35974414
[TBL] [Abstract][Full Text] [Related]
12. Identification of immunotherapy-related lncRNA signature for predicting prognosis, immunotherapy responses and drug candidates in bladder cancer.
Hui P; Ni F; Zheng L; Jia L; Wang Z
BMC Cancer; 2023 Apr; 23(1):355. PubMed ID: 37072750
[TBL] [Abstract][Full Text] [Related]
13. An exosome-derived lncRNA signature identified by machine learning associated with prognosis and biomarkers for immunotherapy in ovarian cancer.
Cui Y; Zhang W; Lu W; Feng Y; Wu X; Zhuo Z; Zhang D; Zhang Y
Front Immunol; 2024; 15():1228235. PubMed ID: 38404588
[TBL] [Abstract][Full Text] [Related]
14. MIR155HG is a prognostic biomarker and associated with immune infiltration and immune checkpoint molecules expression in multiple cancers.
Peng L; Chen Z; Chen Y; Wang X; Tang N
Cancer Med; 2019 Dec; 8(17):7161-7173. PubMed ID: 31568700
[TBL] [Abstract][Full Text] [Related]
15. A pyroptosis-related lncRNA signature in bladder cancer.
Wang P; Wang Z; Zhu L; Sun Y; Castellano L; Stebbing J; Yu Z; Peng L
Cancer Med; 2023 Mar; 12(5):6348-6364. PubMed ID: 36237132
[TBL] [Abstract][Full Text] [Related]
16. Immune gene patterns and characterization of the tumor immune microenvironment associated with cancer immunotherapy efficacy.
Lin L; Zhang W; Chen Y; Ren W; Zhao J; Ouyang W; He Z; Su W; Yao H; Yu Y
Heliyon; 2023 Mar; 9(3):e14450. PubMed ID: 36950600
[TBL] [Abstract][Full Text] [Related]
17. Clinical Importance of the lncRNA NEAT1 in Cancer Patients Treated with Immune Checkpoint Inhibitors.
Toker J; Iorgulescu JB; Ling AL; Villa GR; Gadet JAMA; Parida L; Getz G; Wu CJ; Reardon DA; Chiocca EA; Mineo M
Clin Cancer Res; 2023 Jun; 29(12):2226-2238. PubMed ID: 37053197
[TBL] [Abstract][Full Text] [Related]
18. Multi-cohort validation of Ascore: an anoikis-based prognostic signature for predicting disease progression and immunotherapy response in bladder cancer.
Xie T; Peng S; Liu S; Zheng M; Diao W; Ding M; Fu Y; Guo H; Zhao W; Zhuang J
Mol Cancer; 2024 Feb; 23(1):30. PubMed ID: 38341586
[TBL] [Abstract][Full Text] [Related]
19. Predictive Value of the
Pan YH; Zhang JX; Chen X; Liu F; Cao JZ; Chen Y; Chen W; Luo JH
Front Immunol; 2021; 12():643282. PubMed ID: 34421886
[TBL] [Abstract][Full Text] [Related]
20. Discovery and validation of immune-associated long non-coding RNA biomarkers associated with clinically molecular subtype and prognosis in diffuse large B cell lymphoma.
Zhou M; Zhao H; Xu W; Bao S; Cheng L; Sun J
Mol Cancer; 2017 Jan; 16(1):16. PubMed ID: 28103885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]